HTB

Pregnancy

No link between raltegravir and adverse birth outcomes in analysis in 2550 women

Low rates of pregnancy with three methods of contraception in the ECHO trial

Other pregnancy studies IAS 2019

Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals

High rates of viral suppression with low dose efavirenz in pregnant Zambian women

Infant dolutegravir exposure through placental and breastmilk transfer  

Antiretroviral pharmacokinetics in pregnancy: update from IMPAACT P1026s

No increased adverse outcomes among women starting dolutegravir before conception in the ADVANCE study

Integrase inhibitors and neural tube defects: more data still needed

Dear Doctor letter: Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection dues to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy

Dolutegravir suppresses viral load faster than efavirenz in late pregnancy: results from DolPHIN-2

Raltegravir achieves swifter viral load suppression in pregnancy than efavirenz

Hepatitis C is an independent risk factor for preterm delivery in HIV positive women: data from a Warsaw cohort

Vertical transmission remains very low in UK and Ireland: update from the National Study of HIV in Pregnancy and Childhood 

No additional neural tube defects with preconception dolutegravir: data from three birth outcome cohorts

Insufficient data on risk of neural tube defects with exposure to elvitegravir or bictegravir exposure during preconception or first trimester

TAF exposures during pregnancy and postpartum appear adequate but more data are needed

High rate of unintended pregnancy among HIV positive African women on ART

WHO recommends dolutegravir widely but women’s access will depend on contraception provision (2018)

No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018)

Swifter viral load suppression with dolutegravir vs efavirenz in late pregnancy: results from DolPHIN 1

Preconception safety signal with dolutegravir: data from the Tsepamo study

Dolutegravir preconception signal: time is up for shoddy surveillance

Dolutegravir: need to consider all pros and cons before switching in pregnancy

Why U=U does not apply to breastfeeding

Janssen Dear Doctor letter: Prezista (darunavir), Rezolsta ▼(darunavir/cobicistat)and Symtuza ▼(darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model

Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network  

BHIVA statement on potential safety signal in infants born to women conceiving on dolutegravir

ViiV Dear Doctor letter: Neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception

Potential safety signal for dolutegravir from the time of conception

Dolutegravir in pregnancy: early data reassuring but ongoing surveillance is still essential

Almost 1 in 8 people with symptoms turned away from sexual health clinics in SE London: 40% are under 25 and 6% under 18 years old

Key changes to upcoming UK HIV pregnancy guidelines (2018)

Pregnancy studies at 4th Joint BHIVA/BASHH Conference

Isoniazid preventive TB therapy in pregnancy and postpartum: recommendations now need to be re-evaluated

Efavirenz might decrease effectiveness of the vaginal contraceptive ring

Standard dose of dolutegravir sufficient in late pregnancy: interim results from DolPHIN1 study

Standard once-daily dolutegravir dosing achieves target levels during pregnancy

New HIV pregnancy study uses latest ART: IMPAACT 2010 study (VESTED) includes dolutegravir and tenofovir alafenamide (TAF)

Association between timing of maternal ART and risk of infants born small for gestational age in Dutch ATHENA cohort

Dolutegravir use in pregnancy: results from small Belgian cohort

No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load

Reassuring French data using raltegravir during pregnancy

Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold

Experts disagree with controversial BMJ support for older HIV drugs in pregnancy

BHIVA challenges BMJ recommendations on ART during pregnancy: tenofovir still strongly recommend

Preliminary results on dolutegravir use in pregnancy are reassuring

Low dose efavirenz (EFV400) can be used during pregnancy

Stillbirth rate in HIV positive women in UK/Ireland is double that of the general population

Inconsistencies between real-world data from UK and Ireland and EU recommendations for new antiretrovirals in pregnancy

Dolutegravir pharmacokinetics in pregnancy

Option B+ Malawi

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

PrEP in pregnancy does not increase poor birth outcomes

Efavirenz, tenofovir and emtricitabine associated with fewest adverse birth outcomes in Botswana

Adverse pregnancy outcomes and risk factors in the PROMISE trial

Women on lopinavir/ritonavir-based regimens at conception at higher risk of preterm delivery in UK study

No increase in adverse birth outcomes with maternal TDF/FTC in US study

Pregnancy common in ART trials in sub-Saharan Africa despite exclusion criteria

TDF/FTC can be used as PrEP by breastfeeding mothers without risk to the baby

Dolutegravir use in a London cohort – including nine pregnant women

HIV positive and HIV negative pregnancies in the UK and Ireland have similar outcomes including for older women: impressive 15-year review

High risk of virological failure and loss to follow up postpartum in South Africa

Birth weight and preterm delivery outcomes of vertically vs non-vertically infected HIV positive pregnant women

Post navigation